Spyre Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2015 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Spyre Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2015 to Q3 2024.
  • Spyre Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$69M, a 72.1% decline year-over-year.
  • Spyre Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$215M, a 27% increase year-over-year.
  • Spyre Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$339M, a 304% decline from 2022.
  • Spyre Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$83.8M, a 27.4% decline from 2021.
  • Spyre Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$65.8M, a 18.7% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$215M -$69M -$28.9M -72.1% Jul 1, 2024 Sep 30, 2024 10-Q/A 2024-11-18
Q2 2024 -$186M -$38.8M +$178M +82.1% Apr 1, 2024 Jun 30, 2024 10-Q/A 2024-11-18
Q1 2024 -$364M -$43.9M -$25.4M -138% Jan 1, 2024 Mar 31, 2024 10-Q/A 2024-11-18
Q4 2023 -$339M -$63.2M -$44.4M -236% Oct 1, 2023 Dec 31, 2023 10-K/A 2024-11-18
Q3 2023 -$294M -$40.1M -$21.9M -120% Jul 1, 2023 Sep 30, 2023 10-Q/A 2024-11-18
Q2 2023 -$273M -$217M -$195M -872% Apr 1, 2023 Jun 30, 2023 10-Q/A 2024-11-18
Q1 2023 -$77.8M -$18.4M +$6.01M +24.6% Jan 1, 2023 Mar 31, 2023 10-Q/A 2024-11-18
Q4 2022 -$83.8M -$18.8M +$1.62M +7.94% Oct 1, 2022 Dec 31, 2022 10-K/A 2024-11-18
Q3 2022 -$85.4M -$18.2M +$2.07M +10.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$87.5M -$22.3M -$15.5M -227% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-09
Q1 2022 -$72M -$24.4M -$6.22M -34.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-09
Q4 2021 -$65.8M -$20.4M +$2.27M +9.99% Oct 1, 2021 Dec 31, 2021 10-K/A 2024-11-18
Q3 2021 -$68.1M -$20.3M -$2.27M -12.6% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$65.8M -$6.83M +$14.6M +68.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-03
Q1 2021 -$80.4M -$18.2M +$510K +2.72% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-03
Q4 2020 -$80.9M -$22.7M -$1.22M -5.67% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-18
Q3 2020 -$79.7M -$18M +$3.54M +16.4% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$83.2M -$21.4M -$3.4M -18.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-04
Q1 2020 -$79.8M -$18.7M -$1.56M -9.09% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-04
Q4 2019 -$78.3M -$21.5M -$6.6M -44.3% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-18
Q3 2019 -$71.7M -$21.6M -$9.66M -81% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-18
Q2 2019 -$62M -$18M -$8.61M -91.4% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-18
Q1 2019 -$53.4M -$17.2M -$9.05M -111% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-18
Q4 2018 -$44.3M -$14.9M -$8.42M -130% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-24
Q3 2018 -$35.9M -$11.9M -$4.04M -51.3% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-24
Q2 2018 -$31.9M -$9.41M -$2.78M -41.9% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-24
Q1 2018 -$29.1M -$8.12M -$1.87M -30% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-24
Q4 2017 -$27.2M -$6.48M -$1M -18.2% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-07
Q3 2017 -$26.2M -$7.87M -$1.64M -26.2% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-07
Q2 2017 -$24.6M -$6.63M -$1.2M -22.1% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-07
Q1 2017 -$23.4M -$6.25M -$1.7M -37.4% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-07
Q4 2016 -$21.7M -$5.48M -$1.5M -37.5% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-13
Q3 2016 -$20.2M -$6.24M -$2.83M -82.8% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-13
Q2 2016 -$17.4M -$5.43M -$4M -281% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-13
Q1 2016 -$13.4M -$4.55M -$2.08M -84.2% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-13
Q4 2015 -$11.3M -$3.99M Oct 1, 2015 Dec 31, 2015 10-K 2017-03-23
Q3 2015 -$3.41M Jul 1, 2015 Sep 30, 2015 10-K 2017-03-23
Q2 2015 -$1.43M Apr 1, 2015 Jun 30, 2015 10-K 2017-03-23
Q1 2015 -$2.47M Jan 1, 2015 Mar 31, 2015 10-K 2017-03-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.